Sanofi and Regeneron Pharmaceuticals Inc. reported positive preliminary results from the phase 1 trial of REGN2810 in patients with advanced cutaneous squamous cell carcinoma, or CSCC, a type of skin cancer.

Under the trial, treatment with REGN2810 resulted in an investigator-assessed overall response rate of 46.2% and a disease control rate of 69.2%. The median progression-free survival and overall survival were not reached at the data cutoff date with a median follow-up of 6.9 months, the company said in a news release.

Further, one patient experienced progressive disease during treatment of the drug after the initial response, while two patients were not evaluable due to death unrelated to the treatment.

REGN2810 is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. The treatment is also being investigated in a phase 2 trial that is currently enrolling CSCC patients.